Review





Similar Products

pronase e  (MedChemExpress)
95
MedChemExpress pronase e
DMNQ binds to the SH2 domain of STAT3 and inhibits its phosphorylation A Venn diagram of DMNQ targets screened from the SuperPred database and gastric cancer therapeutic targets (GC 0349530). B Molecular docking results between DMNQ and its potential target STAT3 were obtained via MOE and PyMOL. C Western blot (WB) analysis of tSTAT3 and pSTAT3 levels in gastric cancer cells treated with DMNQ. D Molecular dynamics simulation of the DMNQ-STAT3 complex were performed via Yasara software. E After 48 h of DMNQ treatment, a CETSA assay was conducted; the protein stability of STAT3 was examined via WB at 40–80 °C. F The STAT3 protein was mutated (S611A/E612A/S613A), followed by 48 h of DMNQ treatment. A CETSA assay was then performed, and the protein stability of STAT3 was examined via WB at 40–80 °C. G Cell lysates were incubated with DMNQ at different concentrations and digested with pronase E, and the reaction was terminated by adding the corresponding enzyme inhibitor. The protein level of STAT3 was detected by WB. H After 48 h of DMNQ treatment, the level of pSTAT3 in gastric cancer cells was detected by immunofluorescence. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Pronase E, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pronase e/product/MedChemExpress
Average 95 stars, based on 1 article reviews
pronase e - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
c11965500bt pronase e mce  (MedChemExpress)
95
MedChemExpress c11965500bt pronase e mce
DMNQ binds to the SH2 domain of STAT3 and inhibits its phosphorylation A Venn diagram of DMNQ targets screened from the SuperPred database and gastric cancer therapeutic targets (GC 0349530). B Molecular docking results between DMNQ and its potential target STAT3 were obtained via MOE and PyMOL. C Western blot (WB) analysis of tSTAT3 and pSTAT3 levels in gastric cancer cells treated with DMNQ. D Molecular dynamics simulation of the DMNQ-STAT3 complex were performed via Yasara software. E After 48 h of DMNQ treatment, a CETSA assay was conducted; the protein stability of STAT3 was examined via WB at 40–80 °C. F The STAT3 protein was mutated (S611A/E612A/S613A), followed by 48 h of DMNQ treatment. A CETSA assay was then performed, and the protein stability of STAT3 was examined via WB at 40–80 °C. G Cell lysates were incubated with DMNQ at different concentrations and digested with pronase E, and the reaction was terminated by adding the corresponding enzyme inhibitor. The protein level of STAT3 was detected by WB. H After 48 h of DMNQ treatment, the level of pSTAT3 in gastric cancer cells was detected by immunofluorescence. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
C11965500bt Pronase E Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c11965500bt pronase e mce/product/MedChemExpress
Average 95 stars, based on 1 article reviews
c11965500bt pronase e mce - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
pronasee  (MedChemExpress)
95
MedChemExpress pronasee
DMNQ binds to the SH2 domain of STAT3 and inhibits its phosphorylation A Venn diagram of DMNQ targets screened from the SuperPred database and gastric cancer therapeutic targets (GC 0349530). B Molecular docking results between DMNQ and its potential target STAT3 were obtained via MOE and PyMOL. C Western blot (WB) analysis of tSTAT3 and pSTAT3 levels in gastric cancer cells treated with DMNQ. D Molecular dynamics simulation of the DMNQ-STAT3 complex were performed via Yasara software. E After 48 h of DMNQ treatment, a CETSA assay was conducted; the protein stability of STAT3 was examined via WB at 40–80 °C. F The STAT3 protein was mutated (S611A/E612A/S613A), followed by 48 h of DMNQ treatment. A CETSA assay was then performed, and the protein stability of STAT3 was examined via WB at 40–80 °C. G Cell lysates were incubated with DMNQ at different concentrations and digested with pronase E, and the reaction was terminated by adding the corresponding enzyme inhibitor. The protein level of STAT3 was detected by WB. H After 48 h of DMNQ treatment, the level of pSTAT3 in gastric cancer cells was detected by immunofluorescence. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Pronasee, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pronasee/product/MedChemExpress
Average 95 stars, based on 1 article reviews
pronasee - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
pronase solution  (MedChemExpress)
94
MedChemExpress pronase solution
DMNQ binds to the SH2 domain of STAT3 and inhibits its phosphorylation A Venn diagram of DMNQ targets screened from the SuperPred database and gastric cancer therapeutic targets (GC 0349530). B Molecular docking results between DMNQ and its potential target STAT3 were obtained via MOE and PyMOL. C Western blot (WB) analysis of tSTAT3 and pSTAT3 levels in gastric cancer cells treated with DMNQ. D Molecular dynamics simulation of the DMNQ-STAT3 complex were performed via Yasara software. E After 48 h of DMNQ treatment, a CETSA assay was conducted; the protein stability of STAT3 was examined via WB at 40–80 °C. F The STAT3 protein was mutated (S611A/E612A/S613A), followed by 48 h of DMNQ treatment. A CETSA assay was then performed, and the protein stability of STAT3 was examined via WB at 40–80 °C. G Cell lysates were incubated with DMNQ at different concentrations and digested with pronase E, and the reaction was terminated by adding the corresponding enzyme inhibitor. The protein level of STAT3 was detected by WB. H After 48 h of DMNQ treatment, the level of pSTAT3 in gastric cancer cells was detected by immunofluorescence. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Pronase Solution, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pronase solution/product/MedChemExpress
Average 94 stars, based on 1 article reviews
pronase solution - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
pronase  (MedChemExpress)
94
MedChemExpress pronase
DMNQ binds to the SH2 domain of STAT3 and inhibits its phosphorylation A Venn diagram of DMNQ targets screened from the SuperPred database and gastric cancer therapeutic targets (GC 0349530). B Molecular docking results between DMNQ and its potential target STAT3 were obtained via MOE and PyMOL. C Western blot (WB) analysis of tSTAT3 and pSTAT3 levels in gastric cancer cells treated with DMNQ. D Molecular dynamics simulation of the DMNQ-STAT3 complex were performed via Yasara software. E After 48 h of DMNQ treatment, a CETSA assay was conducted; the protein stability of STAT3 was examined via WB at 40–80 °C. F The STAT3 protein was mutated (S611A/E612A/S613A), followed by 48 h of DMNQ treatment. A CETSA assay was then performed, and the protein stability of STAT3 was examined via WB at 40–80 °C. G Cell lysates were incubated with DMNQ at different concentrations and digested with pronase E, and the reaction was terminated by adding the corresponding enzyme inhibitor. The protein level of STAT3 was detected by WB. H After 48 h of DMNQ treatment, the level of pSTAT3 in gastric cancer cells was detected by immunofluorescence. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Pronase, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pronase/product/MedChemExpress
Average 94 stars, based on 1 article reviews
pronase - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


DMNQ binds to the SH2 domain of STAT3 and inhibits its phosphorylation A Venn diagram of DMNQ targets screened from the SuperPred database and gastric cancer therapeutic targets (GC 0349530). B Molecular docking results between DMNQ and its potential target STAT3 were obtained via MOE and PyMOL. C Western blot (WB) analysis of tSTAT3 and pSTAT3 levels in gastric cancer cells treated with DMNQ. D Molecular dynamics simulation of the DMNQ-STAT3 complex were performed via Yasara software. E After 48 h of DMNQ treatment, a CETSA assay was conducted; the protein stability of STAT3 was examined via WB at 40–80 °C. F The STAT3 protein was mutated (S611A/E612A/S613A), followed by 48 h of DMNQ treatment. A CETSA assay was then performed, and the protein stability of STAT3 was examined via WB at 40–80 °C. G Cell lysates were incubated with DMNQ at different concentrations and digested with pronase E, and the reaction was terminated by adding the corresponding enzyme inhibitor. The protein level of STAT3 was detected by WB. H After 48 h of DMNQ treatment, the level of pSTAT3 in gastric cancer cells was detected by immunofluorescence. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Redox Biology

Article Title: DMNQ induces ferroptosis and augments the efficacy of anti-PD-L1 immunotherapy in gastric cancer via the STAT3/SLC1A4 axis to mediate cysteine metabolism reprogramming

doi: 10.1016/j.redox.2026.104055

Figure Lengend Snippet: DMNQ binds to the SH2 domain of STAT3 and inhibits its phosphorylation A Venn diagram of DMNQ targets screened from the SuperPred database and gastric cancer therapeutic targets (GC 0349530). B Molecular docking results between DMNQ and its potential target STAT3 were obtained via MOE and PyMOL. C Western blot (WB) analysis of tSTAT3 and pSTAT3 levels in gastric cancer cells treated with DMNQ. D Molecular dynamics simulation of the DMNQ-STAT3 complex were performed via Yasara software. E After 48 h of DMNQ treatment, a CETSA assay was conducted; the protein stability of STAT3 was examined via WB at 40–80 °C. F The STAT3 protein was mutated (S611A/E612A/S613A), followed by 48 h of DMNQ treatment. A CETSA assay was then performed, and the protein stability of STAT3 was examined via WB at 40–80 °C. G Cell lysates were incubated with DMNQ at different concentrations and digested with pronase E, and the reaction was terminated by adding the corresponding enzyme inhibitor. The protein level of STAT3 was detected by WB. H After 48 h of DMNQ treatment, the level of pSTAT3 in gastric cancer cells was detected by immunofluorescence. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The cell lysates were then aliquoted into separate tubes and incubated with various concentrations of DMNQ (MKN-45: 0, 20, 40, 60, 80 μM; MFC: 0, 6, 12, 18, 24 μM) at 37 °C for 1 h. Following DMNQ treatment, the samples were hydrolyzed with pronase E (MKN-45: 20 μg/mL; MFC: 10 μg/mL, MCE; Shanghai, China) at 37 °C for 20 min.

Techniques: Phospho-proteomics, Biomarker Discovery, Western Blot, Software, Incubation, Immunofluorescence